Cargando…

Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness

It has been suggested that urinary PCA3 and TMPRSS2:ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2:ERG (T2) scores w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tallon, Lucile, Luangphakdy, Devillier, Ruffion, Alain, Colombel, Marc, Devonec, Marian, Champetier, Denis, Paparel, Philippe, Decaussin-Petrucci, Myriam, Perrin, Paul, Vlaeminck-Guillem, Virginie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159795/ https://www.ncbi.nlm.nih.gov/pubmed/25079439 http://dx.doi.org/10.3390/ijms150813299

Ejemplares similares

PCA3 and PCA3-Based Nomograms Improve Diagnostic Accuracy in Patients Undergoing First Prostate Biopsy
por: Ruffion, Alain, et al.
Publicado: (2013)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

Differentially Expressed Androgen-Regulated Genes in Androgen-Sensitive Tissues Reveal Potential Biomarkers of Early Prostate Cancer
por: Altintas, Dogus Murat, et al.
Publicado: (2013)

PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients
por: Eguchi, Flávia C., et al.
Publicado: (2014)

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Maillet, Denis, et al.
Publicado: (2021)

Evaluation of Tissue PCA3 Expression in Prostate Cancer by RNA in situ Hybridization - A Correlative Study with Urine PCA3 and TMPRSS2-ERG
por: Warrick, Joshua I., et al.
Publicado: (2013)

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)
por: Newcomb, Lisa F., et al.
Publicado: (2019)

Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates
por: Väänänen, Riina-Minna, et al.
Publicado: (2015)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression
por: Piaton, E, et al.
Publicado: (2005)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

Src: Marker or Actor in Prostate Cancer Aggressiveness
por: Vlaeminck-Guillem, Virginie, et al.
Publicado: (2014)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
por: Dudka, Ilona, et al.
Publicado: (2020)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
por: Pérot, Philippe, et al.
Publicado: (2013)

TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
por: Hägglöf, Christina, et al.
Publicado: (2014)

Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer
por: Hansen, Ailin Falkmo, et al.
Publicado: (2016)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway
por: Afshari, Afsoon, et al.
Publicado: (2021)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020)

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
por: Fang, Lei, et al.
Publicado: (2022)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

When Prostate Cancer Circulates in the Bloodstream
por: Vlaeminck-Guillem, Virginie
Publicado: (2015)

Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
por: Vlaeminck-Guillem, Virginie
Publicado: (2018)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG
por: Roberts, Justin M., et al.
Publicado: (2017)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer
por: Urbinati, Giorgia, et al.
Publicado: (2015)

TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
por: Krstanoski, Zoran, et al.
Publicado: (2016)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019)

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8h05dogfrcpju0tfnl8jnjle7v